

**SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
May 13, 2026**

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference May 13, 2026, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given, and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Amy Green
Mychelle Fernandez	Cheryl Andreoli	Steven Robert Head	Karlee Sullivan
Elyse Walk	Elizabeth Montano		
Roberto Aiolfi	Lorena Garcia Menende		
Raphael Park	Stephen Munday		
Smita Chopade	Case McNamara		
Luke Leman			

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the April 08, 2026 IBC Meeting.

II. ANNOUNCEMENTS

IBC Committee Refresher Training will be given directly after today's meeting.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

None.

IV. CONFLICT OF INTEREST

Case McNamara will abstain from voting on protocol #05-13-26-02 for the Bakowski lab.

V. REVIEW OF PROTOCOLS Summary of Discussions: Summaries of each research proposal were thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

FULL COMMITTEE REVIEW

RENEWALS

1. IBC Protocol #: 05-13-26-01, Catz, Sergio
Title of Study: Catz Lab IBC Protocols
Department: Molecular & Cellular Biology
Primary Reviewer: Cheryl Andreoli
Secondary Reviewer: Raphael Park
NIH Guidelines: III-D-1, III-D-2
Agents/Materials: E. coli, Lymphocytic choriomeningitis virus, Lentiviral vectors, Pseudotyped ΔG-GFP (G*ΔG-GFP) rVSV, Pseudomonas aeruginosa, Retroviral Vectors, Salmonella enterica, Staphylococcus aureus, human blood, human cell lines.

Biosafety Level: BSL-2, ABSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of MB 215, 217 completed on 4/13/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study

The BSL-1 location needs to be listed.

Vertebrate or Invertebrate Animals

The timeframe for E. coli model euthanasia needs to be changed to 12-72 hours post injection.

Exposure Control

The method of material transport needs to be clarified.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

2. IBC Protocol #: 05-13-26-02, Bakowski, Malina

Title of Study: Drug discovery for parasitic protozoa infections
Department: Biology- Calibr
Primary Reviewer: Juan de la Torre
Secondary Reviewer: Roberto Aiolfi
NIH Guidelines: III-D-2
Agents/Materials: Trypanosoma cruzi, Leishmania donovani, Leishmania braziliensis, Leishmania major, Leishmania infantum, Cryptosporidium parvum, Cryptosporidium hominis, Leishmania amazonensis, Leishmania mexicana, human cell lines, non-human primate cell lines.
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of Calibr 124, SR 212 completed on 11/25/25.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

Inclusion of a statement identifying *Cryptosporidium parvum* as a Class B bioterrorism agent and describing disinfection/inactivation methods is needed.

Infectious Agents

Clarification as to whether the genetically modified organisms have altered pathogenesis, host range, virulence, or resistance to clinically useful therapeutics is needed.

Vertebrate or Invertebrate Animals

Details regarding the metrics for humane endpoints for immunocompromised mice infected with T. cruzi or Cryptosporidium are needed. Clarification of the amount of blood collected from mice is needed. A description of the disinfectant protocol for Cryptosporidium parvum is needed.

Study Design/Project Description

A detailed description of agent transport and spill response procedures is required, along with aerosol management, decontamination, and emergency spill response procedures for the Flow Cytometry Core. A description of access restrictions and decontamination procedures for IVIS imaging system use, and decontamination procedures, frequency, and aerosol control validation for the BioTek MultiFlo. Inclusion of procedures for exposure reporting, post-exposure evaluation plans, symptom monitoring guidance, as well as restrictions related to immunocompromised personnel restrictions, and pregnancy considerations for *T. cruzi*, *Leishmania*, and *Cryptosporidium* is needed. Contact time for decontaminating *Cryptosporidium* oocysts is needed.

Risk Assessment

A risk assessment summary table for each pathogen including agent risk group, routes of transmission, infectious dose, recommended disinfectants, PPE requirements, spill response, and waste disposal requirements is suggested.

Exposure Control

Pathological waste needs to be selected. A detailed description of waste management is needed.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

3. IBC Protocol #: 05-13-26-03, Hang, Howard

Title of Study: Neurodegeneration Studies

Department: Immunology & Microbiology

Primary Reviewer: Elyse Walk

Secondary Reviewer: Mychelle Fernandez

NIH Guidelines: III-D-4-b

Agents/Materials: Human alpha-synuclein, Mouse alpha-synuclein, human cell lines.

Biosafety Level: BSL-2+, ABSL-2

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of IMM 115-116 completed on 3/12/26.

Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

The research project description needs to be rewritten to reflect the alpha-synuclein work being performed.

Recombinant and Syn NA

This section needs to be updated to reflect the use of recombinant and synthetic nucleic acids.

Infectious Agents

This section needs to be updated to reflect the use of *Enterococcus*.

Study Design/Project Description

A detailed description of the methodology of forming fibrils is needed.

Review outcome: Not approved; Revisions to be re-reviewed by designated member review.

4. IBC Protocol #: 05-13-26-04, Janda, Kim

Title of Study: Antibody Peptide Tool for Detection of Biological Warfare (BW) and Chemical Warfare (CW) Agents
Department: Chemistry
Primary Reviewer: Case McNamara
Secondary Reviewer: Cheryl Andreoli
NIH Guidelines: N/A
Agents/Materials: botulinum toxin
Biosafety Level: BSL-2
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of BCC 578 completed on 4/23/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Toxins

The maximum amount of toxin stored needs to be made the same between this section and the Study Design section. Out-dated attachments need to be removed.

Study Design/Project Description

A detailed description of the standard cell-based assays needs to be added including the assay format, volume, and toxin concentration.

Exposure Control

Out-dated attachments need to be removed.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

5. IBC Protocol #: 05-13-26-05, Wright, Peter

Title of Study: NMR and biophysical studies of protein structure, dynamics, and function
Department: ISCB
Primary Reviewer: Smita Chopade
Secondary Reviewer: Mychelle Fernandez
NIH Guidelines: III-E-1
Agents/Materials:
Biosafety Level: BSL-1
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of MB 204, 206 completed on 4/16/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study

Indication of the location of centrifuge aerosol containment is needed.

Study Design/Project Description

A brief description of aerosol containment during sonication is necessary.

Exposure Control

BSL-2 training can be removed as a requirement for this protocol.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

6. IBC Protocol #: 05-13-26-06, Cravatt, Benjamin

Title of Study: Studies in Metabolic Pathways and Genome Editing
Department: Chemistry
Primary Reviewer: Smita Chopade
Secondary Reviewer: Michael Bobardt
NIH Guidelines: III-D-1, III-D-2, III-D-4-b, III-E-3
Agents/Materials: Retrovirus, lentivirus, E. coli, human cell lines, non-human primate cell lines.
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of BCC 529, 550, 556 completed on 4/29/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

The IACUC protocols need to be updated and linked, and the external funding box needs to be checked.

Location of Study

Indication of the locations of centrifuge aerosol containment and incubation/shaking is needed.

Toxins

An updated hazard summary needs to be added, and the old documents need to be removed.

Human/Non-human Primate Material

The box for 'Yes' should be selected indicating the use of human/non-human primate material.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

AMENDMENTS

1. IBC Protocol #: 09-11-24-02, Miller, Shannon

Title of Study: Creating synthetic biomolecules using chemical and biological tools to develop therapeutics and methods for discovery
Department: Chemistry
Primary Reviewer: Raphael Park
Secondary Reviewer: Elyse Walk
NIH Guidelines: III-D-1, III-D-2
Agents/Materials: Adeno-associated virus, adenovirus, E. coli, lentivirus, human cell lines, human blood.
Biosafety Level: BSL-2+, ABSL-2
Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of BCC 270, SR 201C completed on 9/5/24.

Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

Mouse work needs to be added to the procedures summary in the containment assessment.

Study Design/Project Description

A detailed description of mouse work needs to be added.

Regulatory Assessment

NIH guideline III-D-4b needs to be selected.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

2. IBC Protocol #: 02-11-26-04, Voss, James

Title of Study: Studies of long-Term Humoral Protection Against Antibody Resistant Pathogens

Department: Immunology & Microbiology

Primary Reviewer: Roberto Aiolfi

Secondary Reviewer: Juan de la Torre

NIH Guidelines: III-D-1, III-D-2, III-D-3, III-D-4-b, III-D-8

Agents/Materials: Adenovirus-associated viral vectors, adenovirus, HIV-1 isolate, lentivirus, Macaque peripheral blood samples

Biosafety Level: BSL-2, ABSL-2

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of IMM 307, 309 completed on 1/20/26.

Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

The IACUC protocol needs to be linked.

Vertebrate or Invertebrate Animals

A description of how HIV is delivered intrarectally as well as a description of how the bedding is handled is needed.

Study Design/Project Description

Confirmation of the length of study and whether HIV work is isolated is needed here. Clarification of when blood collection occurs is also needed.

Risk Assessment

Clarification is required regarding whether animal husbandry will occur during the infectious period.

Exposure Control

The box for 'Materials will be hand-carried/transported on campus and transportation will be on foot' needs to

be selected.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

3. IBC Protocol #: 08-14-24-01, de Carvalho, Renan
Title of Study: Understanding the longevity of immune responses
Department: Immunology & Microbiology
Primary Reviewer: Michael Bobardt
Secondary Reviewer: Elyse Walk
NIH Guidelines: III-D-3
Agents/Materials: Adeno-associated virus, E. coli, Influenza virus, lentivirus, Plasmodium chabaudi, retrovirus.
Biosafety Level: BSL-2+, ABSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of IMM 303, 208C completed on 6/30/24.
Training: Pending training.

The following action items were identified as needing to be updated on the protocol:

General Information

A description of why and how the animals will be taken from the vivarium to the laboratory is needed here.

Review outcome: Conditional approval; full approval granted upon completion of the above-listed action items.

BIOSAFETY REVIEW

1. IBC Protocol #: 11-08-23-01B, Wyatt, Richard
Title of Study: Wyatt Lab Protocol
Department: Immunology & Microbiology
NIH Guidelines: III-D-1, III-D-2, III-E-1
Agents/Materials: HIV pseudoviruses, lentivirus.
Biosafety Level: BSL-2+, ABSL-1
Animal work: ☒ Yes ☐ No
Training: Training verified and on record.

REVIEW OUTCOME: **Approved.**

VI. ADJOURNMENT

The next scheduled IBC meeting is **Wednesday, June 10, 2026**, via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled. Members will be notified via e-mail of meeting cancellations one week before the scheduled meeting.